Wikipedia -WSS

Wikipedia

author：explore 2025-08-19 12:15:01 - browse：2

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Is there really a nursing shortage in the U.S.?

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

Patient advocates sound warning on FDA proposal on salt intake

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Trump's false claims about Georgia's 2020 election long debunked

Health tech investors get more selective as pandemic boom fades

entertainment

Wikipedia

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

STAT Summit: The economic case for universal basic health care

What does generative AI mean for health care? We asked experts

Congress must give Medicare recipients genetic counseling access

Medical leaders decry Supreme Court decision on affirmative action

The problems with dementia villages

Duchenne breakthrough therapy leaves behind pioneering families

UnitedHealth, Optum discontinue NaviHealth name

Sports medicine is finally prioritizing gender equality

Cassava Sciences’ Alzheimer’s clinical trials should be halted

leisure time

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

STAT Readout: Friday, Oct. 20 biotech updates

ProMED sees offers of support, but its future remains unclear

Lung cancer is America's deadliest cancer. Yet so few get screened

Listen: Racing for gene therapy & a pioneering approval

Why a market frenzy over new weight loss drugs defies logic

focus

focus

focus

entertainment